ストックスクリーナーアプリを入手
10.98
6.12%
0.64
前日終値:
$10.34
開ける：
$10.3
24時間の取引高:
348.65K
Relative Volume:
0.44
時価総額：
$627.34M
収益：
$20.72M
当期純損益:
$-100.84M
株価収益率:
-4.1278
EPS:
-2.66
ネットキャッシュフロー:
$-78.56M
1週間 パフォーマンス:
+1.70%
1か月 パフォーマンス:
-2.37%
6か月 パフォーマンス:
+209.10%
1年 パフォーマンス:
+37.34%
1日の値動き範囲:
$10.15
$11.03
1週間の範囲:
$10.04
$11.43
52週間の値動き範囲:
$2.235
$12.34
4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile
名前
4 D Molecular Therapeutics Inc
セクター
電話
(510) 505-2680
住所
5858 HORTON STREET #455, EMERYVILLE
FDMT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
FDMT
4 D Molecular Therapeutics Inc
|
10.98 | 590.78M | 20.72M | -100.84M | -78.56M | -2.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
435.01 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
761.11 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.15 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
922.65 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
200.22 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-07 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2025-01-13 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2024-11-21 | 開始されました | Morgan Stanley | Underweight |
| 2024-09-23 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2024-04-15 | 開始されました | Barclays | Overweight |
| 2024-02-07 | 再開されました | Goldman | Buy |
| 2023-10-26 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-10-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-10-18 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2023-07-05 | 開始されました | Chardan Capital Markets | Buy |
| 2023-01-30 | 開始されました | BMO Capital Markets | Outperform |
| 2022-11-18 | 開始されました | H.C. Wainwright | Buy |
| 2022-11-15 | アップグレード | Goldman | Neutral → Buy |
| 2022-08-12 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2022-06-22 | 開始されました | Jefferies | Buy |
| 2022-01-04 | 開始されました | SVB Leerink | Outperform |
| 2021-01-05 | 開始されました | BofA Securities | Buy |
| 2021-01-05 | 開始されました | Evercore ISI | Outperform |
| 2021-01-05 | 開始されました | Goldman | Neutral |
すべてを表示
4 D Molecular Therapeutics Inc (FDMT) 最新ニュース
Insider Selling: 4D Molecular Therapeutics (NASDAQ:FDMT) Insider Sells $17,314.65 in Stock - MarketBeat
4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price Up 6.2%What's Next? - MarketBeat
4D Molecular Therapeutics (NASDAQ: FDMT) to join Evercore Healthcare Conference fireside chat - Stock Titan
4d Molecular Therapeutics chief legal officer sells $17k in stock - Investing.com Canada
Published on: 2025-11-19 17:30:27 - newser.com
Analysts Offer Insights on Healthcare Companies: GeoVax Labs (GOVX) and 4D Molecular Therapeutics (FDMT) - The Globe and Mail
What recovery options are there for 4D Molecular Therapeutics Inc.July 2025 Catalysts & Capital Efficiency Focused Strategies - newser.com
FDMT: 4D-150 achieves up to 92% injection reduction in wet AMD, with global phase III trials underway - TradingView
FDMT: 4D-150 gene therapy offers up to 92% injection reduction and strong safety for retinal disease - TradingView
4D Molecular Therapeutics appoints Kristian Humer as chief financial officer By Investing.com - Investing.com Nigeria
4D Molecular Therapeutics Names Kristian Humer as CFO - MarketScreener
4D Molecular Therapeutics appoints Kristian Humer as chief financial officer - Investing.com
4D Molecular Therapeutics Appoints New Chief Financial Officer - TipRanks
4D Molecular (FDMT) Therapeutics Appoints New CFO to Drive Finan - GuruFocus
4DMT Appoints Kristian Humer as Chief Financial Officer - The Globe and Mail
4D Molecular Therapeutics Appoints Kristian Humer as Chief Financial Officer - Quiver Quantitative
4D Molecular Therapeutics (Nasdaq: FDMT) names Kristian Humer CFO to lead finance - Stock Titan
4D Molecular Therapeutics (NASDAQ:FDMT) Upgraded at Wall Street Zen - MarketBeat
Can 4D Molecular Therapeutics Inc. rally from current levelsMarket Growth Summary & Free Expert Approved Momentum Trade Ideas - newser.com
4DMT Announces New Employment Inducement Grants - Enidnews.com
4DMT (NASDAQ: FDMT) grants 45,400 RSUs to four new employees under 2025 inducement plan - Stock Titan
Leerink Partnrs Issues Pessimistic Outlook for FDMT Earnings - MarketBeat
Promising Outlook for 4D Molecular Therapeutics: Buy Rating Backed by Strategic Partnerships and Strong Financial Position - TipRanks
Institutional investors own a significant stake of 49% in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - simplywall.st
Royal Bank Of Canada Issues Positive Forecast for 4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price - MarketBeat
Barclays Maintains 4D Molecular Therapeutics (FDMT) Overweight Recommendation - Nasdaq
Working capital per share of 4D Molecular Therapeutics, Inc. – NASDAQ:FDMT - TradingView
4D Molecular Therapeutics: Financial Backing Strengthens Clinical Pipeline Prospects - Ad-hoc-news.de
4D Molecular Therapeutics, Inc. (FDMT) Reports Q3 Loss, Lags Revenue Estimates - sharewise.com
4D Molecular Therapeutics Reports Strategic Gains in Q3 2025 - TipRanks
Can 4D Molecular Therapeutics Inc. stock weather global recessionOptions Play & Daily Profit Focused Stock Screening - newser.com
4D Molecular Therapeutics Misses On Revenue But Secures New Funding - Finimize
4D Molecular Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
4D Molecular Therapeutics, Inc. SEC 10-Q Report - TradingView
[10-Q] 4D Molecular Therapeutics, Inc. Quarterly Earnings Report | FDMT SEC FilingForm 10-Q - Stock Titan
[8-K] 4D Molecular Therapeutics, Inc. Reports Material Event | FDMT SEC FilingForm 8-K - Stock Titan
4D Molecular Therapeutics' Q3 revenue misses - TradingView
4DMT Reports Third Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones - The Manila Times
4DMT (NASDAQ: FDMT) signs APAC license for 4D-150: $85M upfront, $50M+ cost sharing - Stock Titan
4D Molecular Therapeutics Closes $93.3 Million Stock Offering - The Globe and Mail
4D Molecular Therapeutics (NASDAQ:FDMT) Raised to Equal Weight at Morgan Stanley - MarketBeat
4D Molecular Therapeutics Inc expected to post a loss of 98 cents a shareEarnings Preview - TradingView
4D Molecular Therapeutics stock rises after pricing $100M offering - MSN
4D Molecular Therapeutics Advances in Macular Degeneration Treatment: A Phase 3 Study Update - MSN
[424B5] 4D Molecular Therapeutics, Inc. Prospectus Supplement (Debt Securities) - Stock Titan
4DMT (NASDAQ: FDMT) to join Jefferies London fireside chat Nov 18, 9:00 a.m. GMT - Stock Titan
4D Molecular (FDMT) Reports Promising PRISM Trial Data for Wet A - GuruFocus
4D Molecular Therapeutics, Inc. Announces Positive Long-Term Data from Phase 1/2 Prism Clinical Trial in Wet AMD Supporting 4D-150's Potential as a Backbone Therapy with Consistent and Durable Benefit over Multiple Years - MarketScreener
4D Molecular Therapeutics Reports Positive Interim Trial Results - TipRanks
4DMT Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants - GlobeNewswire
Shares priced at $10.51 as 4D Molecular Therapeutics (NASDAQ: FDMT) sets $100M offering - Stock Titan
4 D Molecular Therapeutics Inc (FDMT) 財務データ
収益
当期純利益
現金流量
EPS
4 D Molecular Therapeutics Inc (FDMT) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Bizily Scott | Chief Legal Officer |
Nov 17 '25 |
Sale |
10.59 |
1,635 |
17,315 |
3,594 |
1.64%
0.70%
大文字化:
|
ボリューム (24 時間):